Translational Cancer Research Impact Factor, Quartile, Indexing, Ranking

Translational Cancer Research (TCR) is a scholarly journal dedicated to publishing research in the field of Medicine, and Published by AME Publishing Company. The Print-ISSN of Translational Cancer Research is 2218-676X and its abbreviation is Transl Cancer Res.

The Publicaiton fees (APC) is 1390 USD.

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; https://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in PubMed/PubMed Central and Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer, results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards.

• Journal Website
• PubMed
• Scopus
• SCImago